

*program*

Chairs:

**Pietro Lampertico and Heiner Wedemeyer**

**OCTOBER**  
**11-12, 2024**  
**MILAN, ITALY**

Fondazione Cariplo - Conference Center

**Delta** *cure*

**3<sup>rd</sup> International Meeting**



abstract deadline  
**July 29, 2024**

*also online*  [www.deltacure2024.com](http://www.deltacure2024.com)

# Dear Colleagues and Friends,

It's a great pleasure to invite you to the 3<sup>rd</sup> Edition of **Delta Cure International Meeting** to be held in **Milan, Italy, on October 11-12, 2024.**

We are organizing an exciting meeting in a hospitable environment that will certainly favor an important scientific exchange. Infact, the **Delta Cure Meeting** will review the last evidences in terms of virology, pathogenesis and epidemiology, diagnosis and endpoints.

Two full sessions will be dedicated to thoughtfully debate the most recent advances in terms of current and new antiviral treatments. We will also discuss suggestions for treatment algorithms which will be included in a meeting report to be published in a leading journal of the field. The Faculty will involve an excellent panel of Experts who will guide the attendees through all the challenges of this disease. In particular, we want to encourage young scientists to contribute in topical scientific sessions by submitting abstracts.

Milan is a vibrant cosmopolitan center where the various cultures of northern European and Mediterranean countries merge; it has a lot to offer: art museums, history, opera (La Scala), music, fashion, design, culinary delights and business opportunities. Milan is easy to reach by all means of transport, but is one of the most accessible cities in Europe in terms of air links through 3 international airports (Malpensa, Linate and Orio al Serio).

Furthermore, Milan has the largest public transport network which let people travel around the city urban community and the region easily and quickly.

This event will give you the opportunity to focus on the newest scientific trends in our field in an atmosphere of Italian hospitality and the Italian expression of European Union.

We are sure that - forty-five years after the discovery of HDV - this Meeting will shed new exciting lights on the management of this difficult-to-treat disease.

**Looking forward to meeting you in October 2024,**

**Arrivederci in Milan!**

The Chairs  
*Pietro Lampertico and Heiner Wedemeyer*



**Opening Session**

11.20 - 11.30 Welcome by Chairs *P. Lampertico and H. Wedemeyer*

**WHO SESSION Hepatitis Delta: making a difference in low- and middle-income countries**

11.30 - 11.40 Updated WHO HBV guidelines and recommendations for testing and diagnosis for HDV

11.40 - 11.50 Diagnostics for HDV: what we have and what we need for improving diagnosis in low-and-middle income countries

11.50 - 12.00 Hepatitis Delta epidemiology and experiences with HDV diagnosis and reflex testing in Uzbekistan

12.00 - 12.15 HDV diagnosis and treatment in Pakistan and the way forward for LMICs

12.15 - 12.30 Panel discussion

12.30 - 13.30 Light Lunch and Coffee

**SESSION 1 Virology, Pathogenesis and Diagnosis**

13.30 - 13.50 Virology: the latest insights

13.50 - 14.10 Pathogenesis: insights from liver biopsies


14.10 - 14.30 Are immune responses important in HDV infection?

14.30 - 14.50 New HBV biomarkers: any role in HDV?

14.50 - 15.00 Oral presentation (selected abstract)

15.00 - 15.20 Discussion

15.20 - 15.50 Coffee Break and poster viewing



# OCTOBER 11, 2024

OCTOBER  
11-12, 2024  
MILAN, ITALY

**Delta** *Cure*  
3<sup>rd</sup> International Meeting

## SESSION 2

### Diagnosis, staging, HCC risk and antiviral therapy

15.50 - 16.10

HDV-RNA assays: performances and clinical challenges

16.10 - 16.30

Fibroscan and other non-invasive markers

16.30 - 16.50

PegIFN+NUC: predictors of response

16.50 - 17.00

Oral presentation (selected abstract)

17.00 - 17.20

Discussion

## SESSION 3

### Current and new antiviral treatments I

17.20 - 17.40

Bulevirtide mono and combo in clinical trials

17.40 - 17.55

Bulevirtide in EU: SAVE-D study update

17.55 - 18.10

Bulevirtide in France: multicenter study update

18.10 - 18.25

Bulevirtide for decompensated cirrhosis

18.25 - 18.35

Oral presentation (selected abstract)

18.35 - 19.00

Discussion

19.00 - 19.30

State of the Art Lecture and Prize: "My journey with HDV"

19.30 - 20.00

Transfer to the Dinner venue (*walking distance*)

20.00 - 22.30

Apero and Dinner



08.00 - 08.30 Welcome breakfast  
08.30 - 08.50 Opening remarks Day 2 *P. Lampertico and H. Wedemeyer*

**SESSION 4** **Current and new antiviral treatments II**

08.50 - 09.10 Bulevirtide in HIV coinfecting patients  
09.10 - 09.30 Can we stop Bulevirtide? Lessons learned from viral kinetics modelling  
09.30 - 09.50 What have we learned from the Lonafarnib and pegIFN lambda trials?  
09.50 - 10.10 New antivirals for HDV, phase II studies  
10.10 - 10.30 What can we learn from HBV trials for HDV cure?  
10.30 - 10.40 Oral presentation (selected abstract)  
10.40 - 11.00 Discussion

11.00-11.30 Coffee Break and poster viewing


**SESSION 5** **Round Table Discussion**

*Moderators: P. Lampertico and H. Wedemeyer*

11.30 - 12.30 Hot topics in HDV management. Academia, Pharma, Diagnostics, Patient Associations

12.30 - 12.45 Closing remarks *P. Lampertico and H. Wedemeyer*

12.45 - 13.45 Farewell Lunch



## Chairs

Pietro Lampertico

Foundation IRCCS Ca' Granda Ospedale Maggiore  
Policlinico, University of Milan, Milan (Italy)

Heiner Wedemeyer

Hannover Medical School, Hannover (Germany)

## Scientific Secretariat and Abstract Reviewers

Elisabetta Degasperì

Foundation IRCCS Ca' Granda Ospedale Maggiore  
Policlinico, University of Milan, Milan (Italy)

Lisa Sandmann

Hannover Medical School, Hannover (Germany)

OCTOBER  
11-12, 2024  
MILAN, ITALY

DeltaCure  
3<sup>rd</sup> International Meeting

## Congress venue

Fondazione Cariplo - Conference Center  
Via Romagnosi, 8 - 20121 Milan, Italy

## CME Provider & PCO

Effetti srl

Via G.B. Giorgini 16 - 20151 Milan, Italy

Tel. +39 02 3343281 - Fax +39 02 38002105

E-mail: [deltacure2024@effetti.it](mailto:deltacure2024@effetti.it)

Ref.: Elena Fiore - E-mail: [elena.fiore@effetti.it](mailto:elena.fiore@effetti.it)

